SQZ Bio Stock (NYSE:SQZ)
Previous Close
$0.27
52W Range
$0.25 - $3.56
50D Avg
$0.55
200D Avg
$1.24
Market Cap
$12.83M
Avg Vol (3M)
$553.61K
Beta
2.71
Div Yield
-
SQZ Company Profile
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
SQZ Performance
Peer Comparison
Ticker | Company |
---|---|
SNTI | Senti Biosciences, Inc. |
NUVB | Nuvation Bio Inc. |
PMVP | PMV Pharmaceuticals, Inc. |
FRTX | Fresh Tracks Therapeutics, Inc. |
MNPR | Monopar Therapeutics Inc. |
IKT | Inhibikase Therapeutics, Inc. |
SABS | SAB Biotherapeutics, Inc. |
QNRX | Quoin Pharmaceuticals, Ltd. |
FENC | Fennec Pharmaceuticals Inc. |
HILS | Tharimmune, Inc. |
ANTX | AN2 Therapeutics, Inc. |
HOWL | Werewolf Therapeutics, Inc. |
CADL | Candel Therapeutics, Inc. |
PCSA | Processa Pharmaceuticals, Inc. |
THRD | Third Harmonic Bio, Inc. |
ANEB | Anebulo Pharmaceuticals, Inc. |
LIPO | Lipella Pharmaceuticals Inc. |
NLTX | Neurogene Inc. |
KZR | Kezar Life Sciences, Inc. |